Oocyte Vitrification Aided With Latrunculin A

Infertility Clinical Trial

Official title:

Latrunculin A for Oocyte Vitrification

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03678571
• Other study ID #: IbnSina-Oocyte-LA
• Status: Completed
• Phase: N/A
• Start date: September 25, 2018
• Est. completion date: July 15, 2019

Study information

• Verified date: July 2019
• Source: Ibn Sina Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Using cytoskeleton Stabilizer the Latrunculin A would improve the outcome of oocyte vitrification

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: July 15, 2019
• Est. primary completion date: July 1, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 42 Years

Eligibility

Inclusion Criteria:

• indication for oocyte cryopreservation

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Infertility

Intervention

Other:
• Latrunculin A supplemented vitrification medium
Vitrification of human oocyte in medium supplemented with Latrunculin A

Locations

Country	Name	City	State
Egypt	Banon Assiut	Assiut
Egypt	Qena Fertility Center	Qena
Egypt	IbnSina IVF Center, IbnSina Hospital	Sohag

Sponsors (2)

Lead Sponsor	Collaborator
Ibn Sina Hospital	Banoon IVF Center

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival after thawing		6 days after thawing
Secondary	fertilization rate		6 days of culture
Secondary	Rates of blastocyst formation and quality	Number of formed blastocyst and high-quality blastocysts per fertilized oocytes	6 days of culture
Secondary	embryo utilization rate	Number of utilized embryos per fertilized oocytes	6 days of culture
Secondary	clinical pregnancy rate	Number of pregnant women with fetal pulsation per recruited cycles	three months
Secondary	ongoing pregnancy rate		12 months